Shandong Lukang Pharmaceutical operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Lukang Pharmaceutical with three other
companies in this sector in China:
ChangChun High New Technology Industries
sales of 2.37 billion Chinese Renmimbi [US$345.62 million]
of which 79%
Shenzhen Hepalink Pharmaceutical Company Limited
(2.29 billion Chinese Renmimbi [US$333.23 million]
of which 100%
was Pharmaceutical Manufacturing), and
Shanxi Zhendong Pharmaceutical Co Ltd
(2.26 billion Chinese Renmimbi [US$329.20 million]
of which 95%
was Medicine Manufacture and Sale).
During the year ended December of 2015, sales at
Shandong Lukang Pharmaceutical were 2.41 billion Chinese Renmimbi (US$350.64 million).
increase of 4.2%
versus 2014, when the company's sales were 2.31 billion Chinese Renmimbi.
The sales level in 2015 was fairly close to the level five years ago: in 2010, Shandong Lukang Pharmaceutical had sales
of 2.20 billion Chinese Renmimbi.